Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells

Genes and Development

Volumn 29, Issue 20, 2015, Pages 2140-2152

  Dai, Haiming ^a,b,c   Ding, Husheng ^a   Meng, X Wei ^a,b   Peterson, Kevin L ^a   Schneider, Paula A ^a   Karp, Judith E ^d   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

^c HEFEI INSTITUTES OF PHYSICAL SCIENCE   (China)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; BAK; BH3 mimetic

Indexed keywords

BIM PROTEIN; NAVITOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; MCL1 PROTEIN, HUMAN; PROTEIN BCL X; PROTEIN BINDING; RECOMBINANT PROTEIN; SULFONAMIDE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL LYSATE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOWN REGULATION; DRUG SENSITIVITY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LYMPHOMA CELL; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL PERMEABILITY; OLIGOMERIZATION; OUTER MEMBRANE; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; SIGNAL TRANSDUCTION; SIZE EXCLUSION CHROMATOGRAPHY; SURFACE PLASMON RESONANCE; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; JURKAT CELL LINE; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOPHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; BCL-X PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JURKAT CELLS; LEUKEMIA, MYELOID, ACUTE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SULFONAMIDES; TRANSCRIPTIONAL ACTIVATION;

EID: 84944729445     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.267997.115     Document Type: Article

References (71)

1. Antonsson B, Montessuit S, Sanchez B, Martinou JC. 2001. Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 276: 11615-11623.
2. Brouwer JM, Westphal D, Dewson G, Robin AY, Uren RT, Bartolo R, Thompson GV, Colman PM, Kluck RM, Czabotar PE. 2014. Bak core and latch domains separate during activation, and freed core domains form symmetric homodimers. Mol Cell 55: 938-946.
3. Certo M, Moore Vdel G, Nishino M, Wei G, Korsmeyer S, Armstrong SA, Letai A. 2006. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365.
4. Cheng EH, Sheiko TV, Fisher JK, Craigen WJ, Korsmeyer SJ. 2003. VDAC2 inhibits BAK activation and mitochondrial apoptosis. Science 301: 513-517.
5. Chipuk JE, Green DR. 2008. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol 18: 157-164.
6. Chittenden T, Harrington EA, O’Connor R, Flemington C, Lutz RJ, Evan GI, Guild BC. 1995. Induction of apoptosis by the Bcl-2 homologue Bak. Nature 374: 733-736.
7. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. 2002. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 277: 1599-1606.
8. Cragg MS, Jansen ES, Cook M, Harris C, Strasser A, Scott CL. 2008. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 118: 3582-3584.
9. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD, Lee EF, Yao S, Robin AY, Smith BJ, et al. 2013. Bax crystal structures reveal how BH3 domains activate Bax and nucleate its oligomerization to induce apoptosis. Cell 152: 519-531.
10. Czabotar PE, Lessene G, Strasser A, Adams JM. 2014. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15: 49-63.
11. Dai H, Meng XW, Lee S-H, Schneider PA, Kaufmann SH. 2009. Context-dependent Bcl-2/Bak interactions regulate lymphoid cell apoptosis. J Biol Chem 284: 18311-18322.
12. Dai H, Smith A, Meng XW, Schneider PA, Pang Y-P, Kaufmann SH. 2011. Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization. J Cell Biol 194: 39-48.
13. Dai H, Ding H, Meng XW, Lee S-H, Kaufmann SH. 2013. Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance. Cancer Res 73: 6998-7008.
14. Dai H, Pang Y-P, Kaufmann SH. 2014. Evaluation of the BH3-only protein Puma as a direct Bak activator. J Biol Chem 289: 89-99.
15. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. 2007. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell 12: 171-185.
16. Dewson G, Kratina T, Sim HW, Puthalakath H, Adams JM, Colman PM, Kluck RM. 2008. To trigger apoptosis, Bak exposes its BH3 domain and homodimerizes via BH3: groove interactions. Mol Cell 30: 369-380.
17. Dewson G, Kratina T, Czabotar P, Day CL, Adams JM, Kluck RM. 2009. Bak activation for apoptosis involves oligomerization of dimers via their α6 helices. Mol Cell 36: 696-703.
18. Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. 2011. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem 286: 491-501.
19. Edwards AL, Gavathiotis E, LaBelle JL, Braun CR, Opoku-Nsiah KA, Bird GH, Walensky LD. 2013. Multimodal interaction with BCL-2 family proteins underlies the proapoptotic activity of PUMA BH3. Chem Biol 20: 888-902.
20. Farrow SN, White JH, Martinou I, Raven T, Pun KT, Grinham CJ, Martinou JC, Brown R. 1995. Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K. Nature 374: 731-733.
21. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, et al. 2008. BAX activation is initiated at a novel interaction site. Nature 455: 1076-1081.
22. Gupta M, Wahner Hendrickson A, Seongseouk Y, Han JJ, Schneider PA, Stenson M, Wellik L, Shing JC, Peterson KL, Flatten KS, et al. 2012. Dual TORC1/TORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 119: 476-487.
23. Hackbarth JS, Lee S-H, Meng XW, Vroman BT, Kaufmann SH, Karnitz LM. 2004. S-peptide epitope tagging for protein purification, expression monitoring and localization in mammalian cells. BioTechniques 37: 835-839.
24. Hsu YT, Youle RJ. 1997. Nonionic detergents induce dimerization among members of the Bcl-2 family. J Biol Chem 272: 13829-13834.
25. Jiang X, Wang X. 2004. Cytochrome C-mediated apoptosis. Annu Rev Biochem 73: 87-106.
26. Johnstone RW, Ruefli AA, Lowe SW. 2002. Apoptosis. A link between cancer genetics and chemotherapy. Cell 108: 153-164.
27. Kaufmann SH. 2001. Reutilization of immunoblots after chemiluminescent detection. Anal Biochem 296: 283-286.
28. Kaufmann SH, Earnshaw WC. 2000. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49.
29. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng Y-C, Rowinsky EK. 1997. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood 89: 2098-2104.
30. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD. 1998. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 91: 991-1000.
31. Kim H, Tu HC, Ren D, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ, Cheng EH. 2009. Stepwise activation of BAX and BAK by tBID, BIM, andPUMAinitiates mitochondrial apoptosis. Mol Cell 36: 487-499.
32. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DCS, Kimura S, Ottmann OG, Druke BJ, Villunger A, et al. 2006. Bim and Bad mediate imatinib-induced killing of Bcr/ Abl leukemic cells and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad 103: 14907-14912.
33. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneiter R, Green DR, Newmeyer DD. 2002. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 111: 331-342.
34. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. 2002.
35. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192.
36. Leverson JD, Zhang H, Chen J, Tahir SK, Phillips DC, Xue J, Nimmer P, Jin S, Smith M, Xiao Y, et al. 2015. Potent and selective small-molecule MCL-1 inhibitors demonstrate ontarget cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax). Cell Death Dis 6: e1590.
37. Llambi F, Moldoveanu T, Tait SW, Bouchier-Hayes L, Temirov J, McCormick LL, Dillon CP, Green DR. 2011. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 44: 517-531.
38. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, Andrews DW. 2008. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 135: 1074-1084.
39. Ma S, Hockings C, Anwari K, Kratina T, Fennell S, Lazarou M, Ryan MT, Kluck RM, Dewson G. 2013. Assembly of the Bak apoptotic pore: a critical role for the Bak protein α6 helix in the multimerization of homodimers during apoptosis. J Biol Chem 288: 26027-26038.
40. Martinou JC, Youle RJ. 2011. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 21: 92-101.
41. Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, et al. 2007. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 282: 29831-29846.
42. Meng XW, Heldebrant MP, Flatten KS, Loegering DA, Dai H, Schneider PA, Akazawa Y, Trushin S, Smith BD, Karp JE, et al. 2010. Protein kinase Cβ in modulates ligand-induced cell surface death receptor accumulation: a mechanistic basis for enzastaurin-death ligand synergy. J Biol Chem 285: 888-902.
43. Merino D, Giam M, Hughes PD, Siggs OM, Heger K, O’Reilly LA, Adams JM, Strasser A, Lee EF, Fairlie WD, et al. 2009. The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. J Cell Biol 186: 355-362.
44. Moldoveanu T, Liu Q, Tocilj A, Watson M, Shore G, Gehring K. 2006.
45. The X-ray structure of a BAK homodimer reveals an inhibitory zinc binding site. Mol Cell 24: 677-688.
46. Moldoveanu T, Grace CR, Llambi F, Nourse A, Fitzgerald P, Gehring K, Kriwacki RW, Green DR. 2013. BID-induced structural changes in BAK promote apoptosis. Nat Struct Mol Biol 20: 589-597.
47. Montero J, Sarosiek KA, DeAngelo JD, Maertens O, Ryan J, Ercan D, Piao H, Horowitz NS, Berkowitz RS, Matulonis U, et al. 2015. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 160: 977-989.
48. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, et al. 2011. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334: 1129-1133.
49. Oh KJ, Singh P, Lee K, Foss K, Lee S, Park M, Aluvila S, Kim RS, Symersky J, Walters DE. 2010. Conformational changes in BAK, a pore-forming proapoptotic Bcl-2 family member, upon membrane insertion and direct evidence for the existence of BH3-BH3 contact interface in BAK homo-oligomers. J Biol Chem 285: 28924-28937.
50. Oltvai ZN, Milliman CL, Korsmeyer SJ. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74: 609-619.
51. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, et al. 2014. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov 4: 362-375.
52. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. 2005. Apoptosis induced by the kinase inhibitor Bay 43-9006 in human leukemia cells involves downregulation of MCL-1 through inhibition of translation. J Biol Chem 280: 35217-35227.
53. Sarosiek KA, Chi X, Bachman JA, Sims JJ, Montero J, Patel L, Flanagan A, Andrews DW, Sorger P, Letai A. 2013. BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response. Mol Cell 51: 751-765.
54. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, et al. 1997. Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science 275: 983-986.
55. Schellenberg B, Wang P, Keeble JA, Rodriguez-Enriquez R, Walker S, Owens TW, Foster F, Tanianis-Hughes J, Brennan K, Streuli CH, et al. 2013. Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Mol Cell 49: 959-971.
56. Smith AJ, Dai H, Correia C, Lee S-H, Takahashi R, Kaufmann SH. 2011. Noxa/Bcl-2 interactions contribute to bortezomib resistance in human lymphoid cells. J Biol Chem 286: 17682-17692.
57. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, et al. 2013. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 19: 202-208.
58. Strasser A, Cory S, Adams JM. 2011. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 30: 3667-3683.
59. Tan T-T, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, Villunger A, Adams JM, White E. 2005. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 7: 227-238.
60. Taylor RC, Cullen SP, Martin SJ. 2008. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9: 231-241.
61. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P, et al. 2008. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
62. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen LB, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, et al. 2006. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399.
63. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM, Strasser A. 2003. p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science 302: 1036-1038.
64. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. 2012. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151: 344-355.
65. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher J, Smith E, Verdine GL, Korsmeyer SJ. 2006. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 24: 199-210.
66. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M, Thompson CB, Korsmeyer SJ. 2000. tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome C. Genes Dev 14: 2060-2071.
67. Westphal D, Dewson G, Menard M, Frederick P, Iyer S, Bartolo R, Gibson L, Czabotar PE, Smith BJ, Adams JM, et al. 2014. Apoptotic pore formation is associated with in-plane insertion of Bak or Bax central helices into the mitochondrial outer membrane. Proc Natl Acad Sci 111: E4076-4085.
68. Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI, Adams JM, Huang DC. 2005.
69. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 19: 1294-1305.
70. Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE, Ierino H, Lee EF, Fairlie WD, Bouillet P, et al. 2007. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 315: 856-859.
71. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA. 2005. The role of Mcl-1 down-regulation in the proapoptotic activity of the Raf kinase inhibitor BAY 43-9006. Oncogene 24: 6861-6869.